[HTML][HTML] Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk, H Van Tinteren… - Cancer Immunology …, 2014 - Springer
Introduction Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody,
has improved overall survival (OS) in metastatic melanoma in phase III trials. However …
has improved overall survival (OS) in metastatic melanoma in phase III trials. However …
[PDF][PDF] Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk, H van Tinteren… - 2014 - academia.edu
Methods Patients with advanced cutaneous melanoma were treated in the netherlands (nl)
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk, H van Tinteren… - Cancer Immunology …, 2014 - orbit.dtu.dk
Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved
overall survival (OS) in metastatic melanoma in phase III trials. However, about 80% of …
overall survival (OS) in metastatic melanoma in phase III trials. However, about 80% of …
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk… - Cancer Immunology …, 2014 - search.proquest.com
Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved
overall survival (OS) in metastatic melanoma in phase III trials. However, about 80% of …
overall survival (OS) in metastatic melanoma in phase III trials. However, about 80% of …
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
S Kelderman, B Heemskerk, H van Tinteren… - Cancer Immunology …, 2014 - europepmc.org
Methods Patients with advanced cutaneous melanoma were treated in the Netherlands (NL)
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
[HTML][HTML] Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk… - Cancer Immunology …, 2014 - ncbi.nlm.nih.gov
Methods Patients with advanced cutaneous melanoma were treated in the Netherlands (NL)
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
[引用][C] Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman - Cancer Immunol Immunother, 2014 - cir.nii.ac.jp
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic
melanoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
melanoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[PDF][PDF] Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk, H van Tinteren… - 2014 - researchgate.net
Methods Patients with advanced cutaneous melanoma were treated in the Netherlands (NL)
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and …
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk, H van Tinteren… - Cancer Immunology …, 2014 - research.rug.nl
Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved
overall survival (OS) in metastatic melanoma in phase III trials. However, about 80% of …
overall survival (OS) in metastatic melanoma in phase III trials. However, about 80% of …
[引用][C] Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
S Kelderman, B Heemskerk… - Cancer …, 2014 - scholarlypublications …
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
| Scholarly Publications Skip to main content Universiteit Leiden Leiden University Scholarly …
| Scholarly Publications Skip to main content Universiteit Leiden Leiden University Scholarly …
